Dow, S&P 500, Nasdaq Futures Edge Lower As Markets Brace For Nvidia Earnings, Anthropic IPO, Fed Minutes: SMMT, NBIS, HELP, MSTR In Focus - Yahoo Finance
Dow, S&P 500, Nasdaq Futures Edge Lower As Markets Brace For Nvidia Earnings, Anthropic IPO, Fed Minutes: SMMT, NBIS, HELP, MSTR In Focus - Yahoo Finance(摘要待生成)
U.S. Indexes Dropped Monday; Summit Therapeutics Fell Furthest
U.S. Indexes Dropped Monday; Summit Therapeutics Fell Furthest(摘要待生成)
$SMMT stock is down 17% today. Here's what we see in our data. | SMMT Stock News
$SMMT stock is down 17% today. Here's what we see in our data. Quiver Quantitative
Form 8K Summit Therapeutics PLC ADR For: 16 November By Investing.com - Investing.com Australia
Form 8K Summit Therapeutics PLC ADR For: 16 November By Investing.com Investing.com Australia
SMMT Maintained by Barclays -- Price Target Lowered to $18.00 - GuruFocus
SMMT Maintained by Barclays -- Price Target Lowered to $18.00 GuruFocus
Why Is Summit Therapeutics (SMMT) Facing An FDA Setback For Ivonescimab?
Why Is Summit Therapeutics (SMMT) Facing An FDA Setback For Ivonescimab? Yahoo Finance
Summit Therapeutics stock hits 52-week low at $12.04 - Investing.com
Summit Therapeutics stock hits 52-week low at $12.04 Investing.com
Summit Therapeutics 8-K (8.01, 9.01): other events
Summit Therapeutics said the FDA issued a Complete Response Letter rejecting ivonescimab’s BLA in its current form, citing lack of statistically significant overall-survival improvement; the HARMONi trial met its progression-free-survival endpoint.
8-K - Summit Therapeutics Inc. (0001599298) (Filer)
8-K - Summit Therapeutics Inc. (0001599298) (Filer)(摘要待生成)
Summit Therapeutics 8-K (2.02, 5.03, 5.07, 9.01): reported results of operations
Summit Therapeutics reported third-quarter and nine-month 2026 results and clinical progress, including a $2 billion post-quarter AstraZeneca equity investment, $629.8 million in quarter-end cash and investments, and statistically significant overall-survival benefits in two Akeso Phase III studies.